None of the patients with response by these criteria developed new lesions at the time of the first follow up scan. In 2 out of Baseline diameter density vs. survival Baseline diameter was significantly associated with PFS and OS, with larger baseline diameters having poorer outcomes. When patients were dichotomized at www.selleckchem.com/products/baricitinib-ly3009104.html the me dian baseline diameter, which Inhibitors,Modulators,Libraries was 38 mm in this cohort, median PFS for patients with baseline diameter 38 mm was 27. 5 months compared with 4. 1 months for those with diameter 38 mm 5. 3, p 0. 007. Each 5 mm increase in baseline diameter increased the hazard of a PFS event by 14%. Median OS was not reached for patients with diameter 38 mm vs. 12. 6 months for those with diameter 38 mm. No deaths occurred in patients with baseline diameters at or below the median.

Each 5 mm increase in baseline diameter in crease the hazard of death by 18%. Baseline density was not associated with PFS 1. 3, p 0. 68 or with OS 0. 7, 95% CI 0. 1 to 4. 0, p 0. 71. Diameter density changes on the 1st follow up and outcome Among the total of 21 patients, 5 patients had pro gressed at the 1st follow up scan while 16 patients had not progressed. Inhibitors,Modulators,Libraries These 16 patients were assessed Inhibitors,Modulators,Libraries using a conditional landmark analysis at 11 weeks. The continuous Cox model, although limited by the small number of patients, sug gested that the percent increase of tumor diameter on the 1st follow up scan result in shorter PFS and OS. Each 5% increase in diameter results in a 13% increase in the hazard of a subsequent PFS event. Each 1% increase in per cent change in diameter increased the risk of death 1.

5 times. Neither the percent Inhibitors,Modulators,Libraries nor absolute change in CT density influenced subsequent PFS or OS. Response by RECIST, MASS and Choi criteria vs survival RECIST and MASS criteria yielded the same 3 re sponders and Inhibitors,Modulators,Libraries were summarized together. No signifi cant PFS or OS differences were observed between RECIST MASS responders vs. non responders. first There was no significant PFS or OS difference between Choi responders vs. non responders. Measurement variability The intra observer agreement was high for both diam eter and density measurements, with CCC of 0. 9865 and 0. 9967, respectively. The 95% limits of agreement were for the sum diameter, and were and for the average density. The inter observer agreement was high for both diameter and density measurements, with CCC of 0. 9774 and 0. 9934, respectively. The 95% limits of agreement were for the sum diameter, and were and for the average density. Discussion The present study demonstrated that 15% tumor dens ity decrease by Choi criteria was noted in one third of the advanced melanoma patients treated with ipilimu mab plus bevacizumab combination therapy at their first follow up CT.